A prospective comparison between liraglutide-plus-basal-insulin combined therapy and intensive insulin therapy in patients with non-insulin-dependent type2 diabetes.

A prospective comparison between liraglutide-plus-basal-insulin combined therapy and intensive insulin therapy in patients with non-insulin-dependent type2 diabetes. - A prospective comparison between liraglutide-plus-basal-insulin combined therapy and intensive insulin therapy in patients with non-insulin-dependent type2 diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028313

Enrollment

Registered

2017-07-25

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Liraglutide-plus-basal-insulin combined therapy. The antidiabetic agent allowed to combination in trial are metformin,pioglitazone, alpha glucosidase inhibitors.(It is only in case of use for more t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The subjects with HbA1c(NGSP)less than 10.0%. 2.The subjects with BMI more than 22kg/m2. 3.The subjects received in glucagon stimulation test for >3 months prior to trial screening,(more than CPR1.0ng/ml before test and also more than 2.0ng/ml after test,the subjects that there are few risks of hyperglycemia even if endogenous insulin secretion is kept and able to replaces bolus insulin with liraglutide.) 4.All subjects had been treated with intensive insulin therapy for >3 months,prior to trial screening. 5.Patients who can understand consent brief and other explanation documents having the ability of agreement about participation in this examination.

Exclusion criteria

Exclusion criteria: 1.Patients with severe ketosis,diabetic coma,the former comatose or type 1 diabetes. 2.Patients with the serious infection,the perioperative period and the serious trauma. 3.Patients with severe renal dysfunction including the patients needing haemodialysis or peritoneal dialysis. 4.Patients with a history of hypersensitivity to liraglutide. 5.Patients with the pregnant woman or the woman who may be pregnant. 6.Patients with serious renal dysfunction,serious liver dysfunction,collagenous or a malignant tumor. 7.In addition,the patient who judged inappropriate by an attendant physician. 8.Patients who take dipeptide-peptidase4 inhibitor,sulfonylurea.

Design outcomes

Primary

Measure	Time frame
The change from baseline in HbA1c after 24 weeks of treatment.	—

Secondary

Measure	Time frame
The change from baseline in bodyweight after 24 weeks of treatment. DTSQs scale score(Diabetes Treatment Satisfaction Questionnaire)	—

Countries

Japan

Contacts

Public ContactSaki Yamamoto

Showa University Division of Diabetes,Metabolism and Endocrinology,Department

sakichakko@gmail.com0337848000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026